(HealthDay)—Netarsudil ophthalmic solution (0.02 percent; once daily) significantly reduced mean intraocular pressure (IOP) among patients with open-angle glaucoma or ocular hypertension, according to a study published in the August issue of the American Journal of Ophthalmology.
In a double-masked, randomized, phase 3, noninferiority study, Albert S. Khouri, M.D., from the Rutgers New Jersey School of Medicine in Newark, and colleagues randomly assigned patients with open-angle glaucoma or ocular hypertension (unmedicated baseline IOP >20 to
The researchers found that daily netarsudil was noninferior to twice-daily timolol, with a mean treated IOP range from 16.3 to 17.9 mm Hg for netarsudil and 16.7 to 17.6 mm Hg for timolol (mean reductions from baseline of 3.9 to 4.7 mm Hg and 3.8 to 5.2 mm Hg, respectively). Netarsudil demonstrated noninferiority to timolol in patients with baseline IOP
“In conclusion, netarsudil [once daily] is effective at lowering IOP in patients with open-angle glaucoma or ocular hypertension, with tolerable ocular adverse events,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Aerie Pharmaceuticals, which manufactures netarsudil and funded the study.
Copyright © 2019 HealthDay. All rights reserved.
Netarsudil lowers IOP in glaucoma, ocular hypertension (2019, August 30)
retrieved 30 August 2019
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.